The PALOMA-1/TRIO-18 trial was a randomized phase 2 trial designed to evaluate the addition of palbociclib to letrozole therapy in patients who had received no prior treatment for ER-positive, HER2-negative advanced breast cancer (ABC). This evidence concerns the gene ERBB2 and breast cancer.